Facial treatments will lead Aarskog-Scott syndrome treatment sales through 2036 with 34.2% of the category segment in 2026. Growth hormone therapy leads with a 29.6% share. The market was valued at USD 3.60 billion in 2025 and is expected to reach USD 6.83 billion by 2036, creating an incremental opportunity of USD 3.02 billion.